Overview
MIS-C is now widely reported around the world in association with the Covid-19 pandemic. Children and adolescents with fever of 3 or more days, with or without a past history of acute COVID infection or known COVID contact, may have MIS-C. Shock, abdominal pain or significant vomiting/diarrhea are prominent features of MIS-C. MIS-C mimics Kawasaki Disease and Toxic Shock Syndrome (TSS). Do not delay anti-microbial therapy because you suspect MIS-C, as it is a diagnosis of exclusion.
In the Key Links tab there is a link to the 2021 UK Consensus Management Guideline for MIS-C, which has been re-named pediatric inflammatory multisystem temporally associated with Covid-19 (PIMS-TS).
Most Recent References
Multisystem inflammatory syndrome in children: A systemic review. Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, Acosta S, Naqvi R, Burmeister-Morton F, Burmeister F, Tarriela A, Petershack M, Evans M, Hoang A, Rajasekaran K, Ahuja S, Moreira A. EClinicalMedicine. 2020 Sep;26:100527
Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. Lara S Shekerdemian, Nabihah R Mahmood, Katie K Wolfe, Becky J Riggs, Catherine E Ross, Christine A McKiernan, Sabrina M Heidemann, Lawrence C Kleinman, Anita I Sen, Mark W Hall, Margaret A Priestley, John K McGuire, Konstantinos Boukas, Matthew P Sharron, Jeffrey P Burns, International COVID-19 PICU Collaborative. JAMA Pediatr. 2020 Sep 1;174(9):868-873
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S.Clin Rheumatol. 2020 Jul;39(7):2085-2094